Neumedicines Inc.
Clinical-stage biopharmaceutical company focused on development of a recombinant human interleukin-12 therapeutic (rHuIL-12) for oncology (combination with standard-of-care therapies) and as a medical countermeasure for hematopoietic syndrome of acute radiation exposure. The company conducts preclinical and clinical development, including randomized and single-arm studies, and collaborates with academic medical centers.
Industries
Nr. of Employees
small (1-50)
Neumedicines Inc.
Pasadena, California, United States, North America
Products
Recombinant human interleukin-12 therapeutic (rHuIL-12)
A recombinant interleukin-12 biologic candidate developed for use as a combination immunotherapeutic in oncology and as a medical countermeasure to mitigate hematopoietic syndrome after radiation exposure.
Recombinant human interleukin-12 therapeutic (rHuIL-12)
A recombinant interleukin-12 biologic candidate developed for use as a combination immunotherapeutic in oncology and as a medical countermeasure to mitigate hematopoietic syndrome after radiation exposure.
Services
Collaborative clinical research
Partnerships with academic medical centers to design and run clinical studies combining biologic therapeutics with standard-of-care treatments.
Collaborative clinical research
Partnerships with academic medical centers to design and run clinical studies combining biologic therapeutics with standard-of-care treatments.
Expertise Areas
- Immuno-oncology
- Clinical trial management
- Biologic (cytokine) drug development
- Hematopoiesis and radiomitigation research
Key Technologies
- Recombinant cytokine therapeutics (rHuIL-12)
- In vivo efficacy models (rodent, canine, non-human primate)
- Cytokine and chemokine assays (IFN-γ, IL-18, CXCL9/10/11)
- Pharmacokinetic/pharmacodynamic analysis